feel better live longer making difference ever day corporate responsibility report maikminpgr oav idnigff ehreeanlcthe eevveerryy ddaay contents front cover introduction chairman community investment sri lankan mothers children waiting chief executive officer business ethics integrity line receive gsks albendazole gsk environment health safety another medication part global managing corporate responsibility valuing people programme eliminate lymphatic summary indicators research development filariasis lf see story contribution society discussion others medicines developing world web references highlights humanitarian product community investment donations valued valued million million million combivir supplied developing albendazole treatments donated countries preferential prices fight lymphatic filariasis notforprofit price combivir reduced corporate responsibility principles formally adopted greenhouse gas emissions per unit sales managers certified compliance code conducttoday corporate responsibility particular resonance pharmaceutical sector business creating medicines treat prevent disease something society needs values time healthcare financing way delivered provokes much debate report deals important issues embarked programme continual business explains improvement environment health safety possible performance tenyear plan excellence included performance measures includes detailed measures targets area show progress already well way meeting targets first five years significant achievements year include programmes developing world introduced new marketing codes example lymphatic filariasis lf elephantiasis backed highest level board debilitating disease affecting million heads business divisions people medicine albendazole helps prevent efforts reinforce codes leave transmission lf partnership doubt acceptable world health organization donated seriousness contravening codes million treatments target eliminate lf time expect gsk always committed achieving donated billion treatments worth around performance integrity profits without billion one pharmaceutical principles sustainable provide clarity industry 's largest donation programmes means adopted new corporate responsibility principles expect continue research development everyone gsk consider apply treatments diseases developing work world effort complemented access initiatives particularly aids africa look forward reporting progress least developed countries preferential next year pricing agreements well established however real progress addressing disease suffering poor countries occur responsibility shared sectors global society governments international agencies sir christopher hogg jp garnier companies gsk chairman chief executive officer corporate responsibility report gsk glaxosmithkline gsk leading researchbased pharmaceutical company make prescription medicines vaccines overthecounter medicines oral care nutritional healthcare products global company headquartered uk major operations us business accounts seven per cent world 's pharmaceutical market particularly strong positions several therapeutic areas including respiratory antiviral central nervous system diabetes vaccines company statistics financial profile operations sales countries trading profit business performance manufacturing facilities rd spend rd facilities sales employment us pharmaceuticals total employees europe pharmaceuticals manufacturing sales marketing international rd pharmaceuticals administration consumer healthcare report report summarises gsks corporate responsibility activity performance information issues covered report available website wwwgskcom corporate responsibility report managing corporate responsibility gsk formally adopted corporate responsibility principles clearly identify key corporate responsibility cr issues provide guidance employees standards company committed corporate responsibility principles standards ethical mission business improve quality conduct human life enable people feel better live expect employees meet high ethical longer focuses needs patients achieve standards aspects business mission products activities conducting activities honesty integrity adhering cr principles enhancing contribution make society sustaining complying applicable laws regulations economic performance operating environmentally responsible manner employment practices leadership advocacy research innovation treat employees respect establish challenging standards undertaking research innovating dignity encourage diversity ensure fair corporate responsibility appropriate may explore apply new technologies treatment phases employment complexities specific needs business constructively engage stakeholders provide safe healthy working building external guidelines experience concerns may arise environment support employees perform share best practice seek influence ensure products subject full potential take responsibility others remaining competitive order rigorous scientific evaluation testing performance reputation business sustain business safety effectiveness quality comply exceed regulations legal standards applicable research development products human rights community investment products customers committed upholding un make positive contribution promote products line high universal declaration human rights communities operate ethical medical scientific standards oecd guidelines mnes core labour invest health education programmes comply applicable laws regulations standards set international labour partnerships aim bring sustainable organisation expect standards improvements underserved people suppliers contractors business developed developing world partners working gsks behalf access medicines engagement caring stakeholders environment continue research develop medicines treat diseases developing want understand concerns operate environmentally responsible world find sustainable ways improve interest corporate responsibility manner systematic management access medicines disadvantaged people issues engage range environmental impacts measurement seek partnerships support activity stakeholders communicate openly performance setting challenging performance addressing cr issues targets improve efficiency ways aim meet needs different activities minimise material energy use groups allowing us pursue legitimate waste generated aim find opportunities business goals use renewable materials recycle waste corporate responsibility report pharmaceutical sector needs demonstrate responsibility across wide range issues gsk shown aware key cr issues clear structures managing gsk management keeps cr committee informed activities responsive committees suggestions donald mchenry chairman corporate responsibility committee corporate responsibility committee gsks corporate responsibility committee consists four nonexecutive directors reports board committee met three times reviewed activity number areas including donations community investment consumer advertising corporate responsibility management reporting political activity programmes diseases developing world donald mchenry dr michle barzach sir christopher hogg dr lucy shapiro chairman corporate dr barzach member sir christopher nonexecutive dr shapiro ludwig professor responsibility committee mr international cooperation high chairman reuters group plc cancer research department mchenry distinguished professor council chairman board member supervisory board developmental biology director practice diplomacy equilibres et populations director air liquide sa chairman beckman centre molecular school foreign service board project hope royal national theatre well genetic medicine stanford georgetown university international consultant health nonexecutive chairman university school medicine president irc group llc strategy formerly french gsk minister health family management corporate responsibility believe corporate responsibility effectively managed within business operations experts cr issues employed corporate gsk board responsibility small corporate team committee coordinates policy development ethics integrity reporting communication socially responsible investors ceo access medicines gsk research innovation corporate executive stakeholder team engagement human rights corporate responsibility community strategy reporting investment employment practices environment products advocacy customers corporate responsibility report key impact areas summary indicators medicines developing world main indicators using track researrcehs etaor cfihn dto rfeinadtm treenattsm feonr tdsi sfeoar sdeiss eoafses deovfe tlohpe indgev weloorpldin g pwroovrilddin pgr ovvaicdciinnge performance range corporate responsibility issues mveadccicinineess afnodr tmhee dpiocionreess tf ocro uthnet rpieoso aretst preferceonutinatl rpiersic aets p referential prices pagepage issue community investment medicines developing world philanthropic work primarily supply arrangements preferentially priced antiretrovirals arvs focuses health education number countries supplied preferentially priced arvs number combivir tablets shipped number albendazole tablets donated number countries supplied albendazole community investment total community investment expenditure total value product donations including albendazole business ethics integrity total value products donated gsk patient standards behaviour required assistance program employees steps business ethics integrity taking ensure achieved number employees completing certification code conduct environment number contract manufacturers audited environment health safety energy consumption million gigajoules using resources efficiently water consumption million cubic metres minimising impact products ozone depletion potential metered dose inhalers operations environment tonnes cfc equivalent protecting employees ozone depletion potential production tonnes cfc equivalent contractors workplace ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent valuing people hazardous waste disposed thousand tonnes commitment diversity equal health safety opportunity creating working lost time injury illness rate cases per hours worked environment talent lost time injury illness rate contractors working site people thrive cases per hours worked valuing people women management grades research development ethnic diversity people colour us conduct publication research development clinical trials need animal gsk animal research facilities accredited association testing safeguards assessment accreditation laboratory animal care treatment assessing benefits developing performance indicators continue take account views stakeholders corporate responsibility report e v gsk plays important role society research new treatments vaccines product donations preferential pricing developing countries support patients afford medicines examples much contribute day americans access medicines free charge subsidised rates people insurance would otherwise able afford medicines million invested scientific medical research day society relies pharmaceutical industry discover develop medicines future corporate responsibility report e day million gsk vaccines distributed worldwide prevent disease help improve public health albendazole preventative treatments donated people developing countries albendazole helps prevent transmission lymphatic filariasis debilitating disease affecting million people developing countries tablets combivir shipped treat hivaids patients developing countries making antiretrovirals affordable sustainable preferential pricing help tackle global hivaids epidemic corporate responsibility report contributio business developing marketing medicines vaccines improve health quality life millions people around world commercial organisation needs make profits fund future investment pay dividends shareholders believe governments developing world patient assistance program us intergovernmental bodies primarily many people developing world continue gsks patient assistance program pap responsible meeting worlds suffer die preventable treatable us gives lowincome uninsured patients access medicines need health challenges including diseases access afford developing world medicines need adequate healthcare replace functions governments facilities gsk makes major contribution commitment access covers cancer charities support research treatments vaccines treatments medicines available another programmes bridges important ways diseases common developing access significant role play countries providing products preferential prices investing community health people received free pharmaceutical research education programmes described gsk medicines programmes total commitment pap developed countries take medicines almost detail million eligibility criteria granted benefited advances programmes among generous developed world mean us longer risk offered pharmaceutical industry even developed countries sections diseases polio tb society sufficient access medicines patient eligibility determined one major threats less century ago phone call enrolled patient particular concern us many still many serious illnesses receive prescription medicine immediately people covered public private health treatments treatments may local pharmacy addition patients improved insurance helping patients helped find sources funding insurance coverage gain access medicaid aids drug assistance program prescription medicines via number initiatives state childrens health insurance programs discovering developing new medicine state elderly drug assistance programs prevent treat disease expensive average cost million takes gsk first pharmaceutical company company promotes pap two us offer card providing savings medicines websites tell patients support around years low income senior citizens disabled people available help increase takeup orange card available groups gsk invested almost providing savings gsks billion research prescription medicines end patients enrolled programme development gsk also joined six enables us employ pharmaceutical companies offer together leading scientists provide rx card low income patients eligible medicare would otherwise technology need able afford prescription medicines push forward frontiers together rx provides discount different medicines medical science also operate patient assistance program society relies pharmaceutical companies provided medicines worth make investment fund research million provided cost funding resources industry integral minimal cost patients development new medicines us medical insurance may otherwise gone without medicines corporate responsibility report n society important part job helping people baltimore county medical insurance gsks programme makes easy help process quick always hope gsk medicine prescription patients pay two months supply medicine matter drug required invaluable uninsured patients might otherwise choose medicines food literally saves lives wendy freeman case manager baltimore county health department maryland us corporate responsibility report medicines f develop lack access even basic medication healthcare facilities led healthcare crisis developing world gsk committed playing leading role addressing crisis gsks response crisis three elements progress half largely due potential preferential pricing offering antiretrovirals following improvements manufacturing purchasers delaying placement orders arvs hivaids antimalarials economies scale cut notforprofit anticipation new funding sources notforprofit basis vaccines significant prices arvs april october became available early hence discounts poorest countries combivir available day increase shipments year research development investment compared december search new treatments vaccines difficult quantify number patients diseases developing world public sector agreements treated result programmes community investment activities supply arvs countries includes control healthcare provision however partnerships support improving health arv supply agreements employers sub study september unled underserved communities saharan africa accelerating access initiative aai indicates subsaharan africa number patients preferential pricing shipped almost million treated arvs supplied six companies gsk arvs antimalarial medicines preferentially priced combivir tablets aai doubled year available public sector notfor developing countries still small proportion profit prices worlds poorest shipment figures exclude product patients need treatment substantial countries including subsaharan africa sold notforprofit prices west africa coverage requires funding pay better notforprofit prices arvs also available illegally diverted back europe amounting healthcare infrastructure ensure safe private employers subsaharan africa almost quarter notforprofit combivir sales delivery medicines patients provide care treatment uninsured staff year decline shipments second projects fully funded global fund fight aids tb malaria also eligible supply arrangements type customer notforprofit prices available countries negotiate preferential prices middleincome countries casebycase basis notforprofit prices set cover manufacturing distribution costs ensures sustain supply products long patients need world health organization set target treat million hiv positive people developing countries arvs committed making strong contribution achievement goal q q q q q q q q q q q q q employers public hospitals ngos govt non aai aai corporate responsibility report medicines developing world oping world extended voluntary licence pilot projects underway explore world similar group also exists vaccines granted generics manufacturer aspen opportunities extending preferential pricing organisation based belgium pharmacare include sales private wider range medicines sector agreement aspen run partnership ngos zambia malawi progress manufacture sell key gsk arvs across uganda tanzania nigeria early observations february launched new meningitis subsaharan africa public suggest greatest medical need vaccine africa mencevaxacw developed private sectors discussions underway basic essential medicines furthermore even available african second generics manufacturer similar medicines supplied lowest prices countries preferential price one euro licence gsk arvs across africa access treatment may significantly increase per dose without adequate healthcare infrastructure product diversion like seen denies phase ii clinical trials malaria vaccine treatment patients developing countries international community made good children began mozambique partnership undermines preferential price agreements progress supporting access medicines malaria vaccine initiative also help minimise diversion introducing special initiatives particular welcome started phase iii clinical trials latin america access packs differentiate preferentially priced funding initiatives global fund rotavirus vaccine protection products able supply countries us emergency plan aids relief major cause diarrhoea dehydration combivirin special pack well g action plan health resulting diarrhoea lack clean recognises importance preferential pricing water supply causes death half similar efforts underway secure preventing product diversion however million children year developing countries widespread regulatory approval trizivirand much still needs done epivirtablet packs retrovirand epivir human clinical trials hiv vaccine continued solution packs also using different research development year researching several colour arv tablets currently cure many potential hiv vaccines anticipate taking diseases affecting developing countries tb vaccine phase development early applied register number existing treatments becoming less arvs eus antidiversion regulation effective due drug resistance investment october signed technology transfer designed prevent illegal product diversion rd new treatments vaccines supply licence agreement brazilian europe therefore vital publicprivate partnerships ppp government production measles essential fund research mumps rubella vaccine enable commercially viable market potential million children brazil product working many vaccinated next five years governments un agencies global funding bodies area july lapdap antimalarial treatment developed gsk ppp received believe currently company approval uk regulatory agency see researching new vaccines treatments expanded research agreement three whos priority diseases medicines malaria venture developing world hivaids tb malaria includes development cda combination clinical development programmes lapdapand artesunateas well two new classes products relevance developing antimalarial drug discovery world seven aimed specifically diseases disproportionately affect developing phase ii clinical trials sitamaquine new oral countries see table number pre treatment visceral leishmaniasis completed clinical projects also underway kenya india demonstrated promising efficacy clinical studies planned q q q q q q q q q q q q team researchers uk tres cantos discontinued development spain established specifically focus oxibendazole intestinal worms treatment research diseases developing offered advantage existing medicines corporate responsibility report snoillim deppihs stelbat shipments combivir tablets excluding diverted product preferentially priceddevelopment pipeline end diseases relevant developing world pre focus clinical phase phase ii phase iii marketed activity hiv nonnrti ziagenepivir epivir retrovir ccr antagonist ziagen combivir aspartyl protease inhibitor agenerase trizivir nrti lexivatelzir vaccines hiv hepatitis e rotarix rotavirus havrix hepatitis engerix b hepatitis b dengue fever malaria streptorix twinrix hep b infanrix diptheria tetanus n meningitidis spneumoniae paediatric acellular pertussis cervarix hpv tritanrix diptheria tetanus polio sabin polio whole cell pertussis priorix measles mumps typherix typhoid rubella hiberix haemophilus mencevax acw meningitis influenzae type b malaria cda chlorproguanil tafenoquine malarone halfan dapsone artesunate lapdap tb sitamaquine zentel deworming agent visceral leishmaniasis pentostam visceral leishmaniasis submitted approval detailed information product pipeline found annual report tenyear partnership programme community investment aids africa kenwa believes action tb completed research developing countries positive action workshop writing effective programme improved understanding manage large community investment fundraising proposals helped secure grant tb help inhouse development programme developing countries includes global fund fight aids targeted effective treatments donations medicines well financial tb malaria disease practical support public health initiatives education programmes largest gsk france foundation gskendowed supporting clinical trials developing programmes include tackling three major charitable foundation supports range countries assess use arvs resource diseases lymphatic filariasis lf commonly programmes improve access healthcare poor settings seven new studies began sub known elephantiasis hivaids malaria hivpositive people africa particularly saharan africa bringing total women children last five years region includes dart study elimination lymphatic filariasis lf foundation provided million largest adult hiv treatment study africa lf affects million people mostly support programmes african countries involving patients uganda developing countries one worlds zimbabwe supplying drugs eight leading causes permanent disability one progress studies prevention mothertochild hiv billion people almost onefifth worlds positive action supported programmes transmission involving patients population risk lf infection gsk 's partnership organisations developing countries albendazole prevents transmission lf countries also gsk france taken together another medicine foundation supported initiatives pledged hiv treatment regimens complex founding partner whos global program renew commitment five years requiring patients take combination eliminate lf expect donate billion gsk also granted million two years several different tablets different times treatments worth estimated support work two hivaids clinics day increases risk patients missing billion valued wholesale prices malawi uganda dose taking medicine wrong time reduce effectiveness progress gsk african malaria partnership treatment lead drug resistance gsk donated million treatments partnership providing million looking ways simplify treatment regimens albendazole countries donated kickstart funding three years support sought regulatory approval million preventative treatments since malaria education programmes initiatives us europe new fixeddose combination million people programme designed improve prevention epivir ziagen currently used expected eventually reach one billion people management malaria seven african countries separate tablets recommended treatment example support help freedom regimens approved onetablet programmes hivaids hunger develop malaria education module combination would taken day years hivaids programme positive 'credit education ' programme provides would replace two tablets currently taken action worked community level package financial services health twice day support hiv care education prevention business education help poor women fight initiatives positive action partnerships chronic hunger illness poverty october us fda approval secured organisations centre african family lexiva new hiv protease inhibitor currently studies cafs tackle issues stigma progress protease inhibitor offer flexible dosing discrimination significant barrier healthcare contributed first grants partners food water restrictions hope many communities affected hivaids freedom hunger amref plan start launching lexiva also known telzir international also donated plan developing countries cafs provides training courses community international assist relief operations organisations working people affected increase malaria cases sudan following december gsk recognised hiv trained key workers severe flooding leadership alleviating tropical infectious diseases ngos build run effective organisations improving global health american helping people affected hiv wellplaced society tropical medicine hygiene support powerful impact example kenyan network women corporate responsibility report lapdap help us meet urgent need affordable antimalarial treatment use africa shown work cases sp standard treatment failed professor peter winstanley university liverpool lapdap new antimalarial sub saharan africa malaria affects million people every year urgent need new affordable treatments combat disease deal problem resistance existing treatments new antimalarial treatment lapdap launched designed tackle deadly disease developed specifically use subsaharan africa malaria kills one million people every year majority children five initiative brought together gsk drug development researchers scientists africa two leading uk medical schools university liverpool london school hygiene tropical medicine gsk uk government department international development jointly funded development project lapdap approved use uk medicines healthcare products regulatory agency line best medical practice gsk conducting post marketing studies africa confirm longterm safety treatment gsk registering lapdap across subsaharan africa available national malaria control programmes preferential prices treatment already registered african countries also developing cda new lapdap plus artesunate combination therapy medicines malaria venture corporate responsibility report community investment childrens health fund 's referral management initiative homeless disadvantaged children especially vulnerable illness likely suffer acute chronic illnesses asthma many receive vaccinations despite needing specialist care difficult families keep hospital appointments millions children us access healthcare need lack transport doctors disadvantaged communities cultural language institutional barriers transient lifestyle often means lose contact doctor nine years gsk provided million childrens health fund set run referral management initiative rmi helps children referred specialist attend appointments receive care need rmi reminds families appointments phone mail provides doortodoor transport clinics helps communications including providing translation service necessary gsk sole funder rmi provided additional funding help extend programme develop guidance introducing similar initiatives nationwide rmi dramatically increased number children see medical specialist referred approximately children programme getting specialist care need compared initiative began childrens health fund partnership gsk responsible positively transforming lives tens thousands medically underserved children need specialist care irwin redlener president childrens health fund corporate responsibility report community investment concentrate community investment improving health education underserved vulnerable communities worldwide contribution mainly donations medicines financial practical support materials laboratory office equipment identify programmes support medicines among first reach iraq basis need potential conflict began also provided impact commercial business medicines following earthquakes india flooding nicaragua global community investment charitable donations valued million humanitarian donations higher equivalent pretax profits statutory previous years reflecting variability results included million patient supply demand donations year year assistance program medicine donations need humanitarian relief depends low income groups us million events conflict natural disasters also humanitarian product donations also supply product gsk available included management expenses million donation vary excess stock cost running community investment available offered charities programmes placed clearly identified community need addition agreements community investment programmes number charities focus major public health initiatives hiv select products gsk stock fulfil plans malaria lymphatic filariasis see relief programmes emergency aid humanitarian aid supporting communities around world employee involvement supporting communities around world programmes support communities need humanitarian aid throughout world examples aftermath humanitarian disaster vital prevent spread infectious diseases antibiotics play essential role uk gsk impact awards recognise reward donate antibiotics support relief efforts work smaller voluntary organisations countries affected natural disasters war dedicated improving community healthcare donations made ngo partners awarded including americares interchurch medical organisations dealing issues diverse assistance map international project hope sexual abuse mental health problems day organisations request gsk medicines care elderly new life counselling service according needs enables received award work counselling respond quickly emergencies since families affected unrest northern ireland medicines warehouses donated medicines worth delighted million valued wholesale prices excellent work carried new life support relief efforts countries gsk 's counselling service recognised gsk impact award method giving including us patient assistance program honoured national level prestigious award must source product great pride concerned cash des brown mp former minister responsibility health kind social services public safety northern ireland product donations valued wholesale acquisition corporate responsibility report cost relates price gsk charges wholesalers warehousing chains retail pricethe government investment gsk build basic healthcare committed excellence science infrastructure go way education delighted ensuring vulnerable gsk one major sciencebased people suffer due companies imperial college illhealth infant mortality supporting important initiative greta beresford safe childbirth coordinator healthprom rt hon tony blair mp british prime minister speaking launch inspire june gsk helping improve school students young people hiv often face social stigma north america interest achievement science increase discrimination makes hard gsk impact awards recognise notforprofit number science teachers continue living normal lives gsk supporting organisations philadelphia helping inspire innovative scheme postdocs seypa programme combats social improve healthcare awards helped research education scheme gsk exclusion five european countries three community organisations raise funds providing million four years year grant youthled focus recruit new volunteers support greater scheme developed partnership groups young people find solutions numbers people awarded imperial college london specialist problems face include developing organisations dealing schools trust inspire places postdoctoral training help organisations provide better issues child abuse breast cancer researchers specialist science schools support young people affected hiv sexual reproductive health assist science teaching study towards teaching qualification provides azerbaijan home refugees gsk support childrens health fund sponsorship help schools gain specialist providing three years safe enabled improve access healthcare science status childbirth programme improve healthcare homeless children pregnant women reduce infant mortality year support five medical research programme run partnership gsk major supporter university charities whose work aims benefit many charity healthprom azerbaijan ministry north carolina 's innovative travelling science people future gave health uses qualified doctors nurses laboratory destiny laboratory visited research projects run tommys train local healthcare providers underserved secondary schools reached baby charity international spinal research midwives develop healthcare training students programme trust epilepsy research foundation materials local gsk business also helping encourages women minority students national osteoporosis society vaccinate refugee children measles pursue science careers mumps rubella gsk 's positive action programme funding science summer free science ukbased ngo called develop zippys friends schools initiative run education programme aims inspire lowcost health education resource uk partnership children teaches young children pursue science careers students learn prisons community health advice support children skills coping adversities fun handson experiments relate science education chase programme designed family changes bereavement bullying every day life children raise awareness sexual health issues gsks support helped extend participated programme libraries prevent spread hiv tb hepatitis project denmark lithuania goa philadelphia area piloted uk prisons india uk hope programme adapted use resourcepoor settings europe children coping cancer lifethreatening illnesses encouraged rediscover childhood barretstown ireland lenvol camp france donated partnership support programmes gsk employees also gave time help run events children barretstown others provided essential business expertise training barretstown team forged gsk share skills resources great example companies know many firms recognise value partnering charity rather merely donating money james hill chairman barretstown corporate responsibility report million people treated lymphatic filariasis one day using medicines donated gsk sri lankan ministry health mobilised healthcare workers volunteers treat half population risk lf one day million people sri lanka halfway year treatment plan one countries several continents working eliminate lf forever international china working partnership rural nursing excellence programme british australian red cross reaching young thailand helped nurses qualify since people drug users prevent spread started providing support hiv young people took part hospitals clinics gsk donated training programme reached programme provide training young people far women lack nurses major barrier improving healthcare rural areas employee involvement programme encourages take skills many gsk employees volunteer time back benefit villages expertise worthy causes local communities include participating gsks support awardwinning personal hygiene days caring notforprofit organisations sanitation education phase programme run us mentoring school children helped us turn simple partnership amref plan international uk science engineering ambassador idea promoting childrens reducing diarrhoearelated disease school scheme us partnership educational children simple handwashing discovery health international programme expanded fourth country zambia ministry education us gsk matched donations programme couldnt usaid rolled schools million made gsk employees wished better peru ministry health retirees matching gifts program addition million donated gsk partners helping give africa 's children employees united way campaign healthier future integrated matched gsk giving total million chris bale director partnership children management childhood illness imci strategy gsk investment volunteer excellence developed unicef imci aims give programme makes donations registered reduce deaths treatable preventable charities us gsk employees diseases improving skills health workers partners volunteer helping families better care sick children gsk provided funding uk making difference initiative technical expertise initiative provides financial support charities expanded south africa ethiopia gsk employees involved voluntary work namibia nigeria gsks product donations humanitarian relief efforts allow us save lives serve catalyst building sustainable health programmes throughout developing world veronica arroyave director corporate relations map international corporate responsibility report gsk committed ensuring business practices meet high standards employees behave ethically honestly compete fairly avoid conflicts interest section business ensuring compliance departments finance human resources standards particular relating managers expected lead example legal compliance internal audit work marketing teams complying code conduct together monitor compliance policies gsk policies supporting staff applicable laws marketing sales code conduct introduced annual practices monitored internal audit gsks code conduct sets standards certification process managers department audits businesses expect employees meet requires vicepresident level ensure fully investigate suspected breaches employees behave honestly line understand responsibility policies take appropriate disciplinary action company policy law avoid extended certification include midlevel warranted conflicts interest report violations management us uk code unethical behaviour managers participated certification gsk provided input compliance program guidance pharmaceutical help employees understand code employees concerns raise manufacturers developed us health constitutes acceptable unacceptable corporate compliance officer human services office inspector general behaviour practice also issued business unit compliance officers guidance published april employee guide business conduct code confidential po box helplines designed help pharmaceutical companies guide available company stakeholders contact customer response establish effective compliance programmes intranet centres redirect calls appropriate senior prevent unlawful unethical conduct management benchmarking programmes guidelines business ethics integrity corporate responsibility report business ethics integrity marketing practices regional codes introduced across advertising selling medicines company designated area subject regulations set governments champions coordinate distribution medicines agencies gsks internal policies codes training staff codes translated encompass build requirements local languages sales marketing employees receive copy products marketed sales representatives regularly meet doctors training workshops electronic media pharmacists inform ensure staff understand codes medicines approved uses also constitutes acceptable promotional activities performance integrity market products directly consumers employees involved sales marketing permitted receive regular training products aspects absolutely non provide accurate information doctors negotiable adherence specific policies guidance sales marketing employees national level ensure new code major way marketing accurate based valid show scientific evidence complies law committed russell greig president pharmaceuticals international gsk gsk also companywide policy conducting business pharmaceutical marketing promotion activity applies employees agents sets integrity means complying commitment promotional practices fully letter ethical responsible principled patientcentred prohibits bribery law spirit inducements doctors prescribe medicine objective look loopholes creative interpretations law detailed guidance provided international regional industry codes shall benchmark practice adhere including simply compare international federation pharmaceutical manufacturers associations ifpma code competitors satisfied pharmaceutical marketing practices good worse addition gsk developed keeps review regional marketing codes andrew witty president pharmaceuticals europe gsk ensure differences market structure national healthcare systems legal framework appropriately reflected enhancing compliance culture sales regular high road newsletter audio programme marketing help reinforce key points training keep pharmaceutical sales marketing division employees date new developments us introduced programme make business company also established advisory board integrity key requirement initiative called take sales managers across business provide high road ethics legal compliance aims feedback new initiatives help ensure compliance ensure employees understand comply sales programmes practical userfriendly marketing policies compliance department confidential gsk education essential element comprehensive integrity helpline publicised employees paper online manual developed know go questions containing sales marketing policies guidelines concerns sales employees used facility ask employees qas key subjects available questions sales marketing policies employees across us new existing sales marketing employees attend compliance training new computerbased training monitoring behaviour important element modules developed ensuring compliance fulltime project team looked employees completed compliance training detail monitoring processes sales video performing integrity supports training marketing introduced improvements includes perspectives gsk sales people necessary audits conducted key compliance areas past two years corporate responsibility report environme health environment health safety ehs issues managed integrated system ensures issues risks identified training provided targets set audits conducted ehs standards apply throughout operations developed tenyear strategic plan plan excellence environment important environmental issues include systematic plan improve air quality volatile organic compounds vocs environment health safety performance used solvents manufacturing contribute ehs plan excellence longterm goal formation smog drive manufacturing impacts switch using renewable resources climate burning fossil fuels energy operations become increasingly compatible produces carbon dioxide contributes principles sustainable development global warming climate change identified appropriate parameters ozone depletion products track progress main impacts manufacturing processes use cfcs gases following formation gsk established damage ozone layer released baseline values parameters atmosphere set improvement targets achieved end see chart waste raw materials used pharmaceutical production processes important element approach hazardous require special disposal methods consultation people outside gsk either experts community neighbours may water waste water discharges affected sites routinely manufacturing sites require treatment several levels aim stakeholders released access information need opportunity tell us think want us improve corporate responsibility report nt environment health safety safety technological changes improve materials recovery new technology help improve environmental performance gsks manufacturing site ulverston uk introduced new membrane filtration system reduced hazardous waste tonnes emissions vocs tonnes per annum new system saves site around million year ulverston one largest primary manufacturing plants staff acre site situated near lake district area natural beauty ecological importance plant makes active ingredients many antibiotics acetone voc used solvent manufacturing axetil oral antibiotic spray dried process ensures medicines absorbed efficiently stomach gut patients bloodstream acetone also used wash equipment used processing antibiotic residue acetone valuable needs recovered disposal acetone previously done remote area site system inefficient lot product wasted acetone highly flammable pumping across site created potential health safety risk site introduced new membrane filtration system separates antibiotic residues acetone allowing concentrated efficient recovery result installing new equipment overall process become much efficient antibiotic recovered less waste filtration system installed next production building reducing amount solvent transferred across site health safety risks site gsk ceos ehs excellence award work implementing new system corporate responsibility report progress emissions use inhalers causes lost injury time performance relating resources waste manufacturing resulting less ozone disposal climate change air quality depleting potential overall improved targets thermalchemical caught inonbetween percentage reductions achieved health safety motor vehicle accidents shown chart health safety employees overexertionsstrains contractors high priority gsk risks slipstripsfalls made particularly good progress hazards associated products striking againststruck toward targets six areas comparing operations systematically assessed includes contact sharps animal figures year set targets measures taken protect employees insect electricfireexplosion foreign measures normalised sales others coming contact hazards bodiesobjects workplace violence energy consumption associated global warming potential water track number cases injury illness consumption ozone depletion resulting time work set potential production challenging target reducing every ozone depletion potential ancillary sources year cut injury hazardous waste disposed illness rate reduced cfcs used propellants metered dose also monitor causes incidents inhalers mdis also use ozone depleting assess learned avoid similar substances refrigeration patient uses injuries main causes injury slips mdi propellant released trips falls strains overexertion motor atmosphere largest source cfc vehicle accidents deeply regret emissions amounting metric tonnes five workrelated fatalities total releases among gsk employees four died driving factories manufacture mdis second accidents one mesothelioma due significant source refrigeration asbestos exposure addition smallest replacement mdis using cfc one contractor died forklift truck accident propellant alternative technologies cut progress targets lost time injury illness rate energy consumption water consumption odp refrigeration ancillary cfc emissions odp production cfc equivalent emissions volatile organic compound emissions global warming potential energy sources hazardous waste disposed targets except lost time injury illness rate annual target improvements baseline environmental measures normalised sales odp ozone depletion potential global warming potential measured co equivalents explanation ehs data full ehs report website wwwgskcom ehs data yet verified corporate responsibility report valuing valuing people people gsk employs people countries getting best people vital success business key source competitive advantage report twothirds gsk employees work embed gsk spirit culture participate individual appraisal process across operations worldwide performance development planning pdp development diversity initiatives helps employees set objectives rewards introducing human rights standards strong performance helps identify procurement processes training need develop careers part pdp process employees gsk spirit managers assess well sets values qualities expect implemented gsk spirit work employees embrace work significant impact bonus principles payments awarded eligible employees performance integrity entrepreneurial spirit use global survey managers focus innovation help us analyse effectively building sense urgency gsk spirit last year reported passion achievement results generally positive since work taking place getting culture right address areas identified development aim build culture people progress measured next clear companys expectations survey takes place instinctively right thing operations working employees diversity ensure understand adopt principles gsk committed employing diverse gsk spirit approach tailored workforce individual employees reflect local circumstances events including gsk benefit workplace talented workshops team meetings presentations people thrive diversity awards example gsk nigeria used background culture outlook helps us better costumed storyteller introduce spirit understand needs patients customers employees argentina every employee worldwide aim create inclusive work attended halfday culture awareness workshop environment free discrimination grounds race ethnicity gender religion sexual leadership development programmes orientation disability age designed encourage employees apply gsk spirit programmes available held first diversity multicultural managers globally levels year marketing awards philadelphia may people attended leadership edge global awards made annually programme senior managers set demonstrate impact diversity attended leadershipgsk programme improving business performance middle managers programmes designed share best practices around company help managers achieve performance others increase insight differing work styles strengths motivations corporate responsibility report current diversity initiatives include women human rights leadership programme us support compliance human rights requirements career development additionally included one criteria holding women science day uk selecting suppliers also introducing attract female science graduates binding clauses procurement contracts industry also undertaking review require suppliers meet standards uk improve working human rights environment access facilities websites disabled employees potential began incorporating human rights employees visitors conclude clauses central contract templates use early new suppliers process completed also adding clauses widened scope employee contract templates used local operations networks us new groups sales staff delaware valley broad risk human rights issues varies around spread existing network activities includes world appropriate contacting career development programmes asian major existing suppliers assess whether african american hispanic gay lesbian meet standards key suppliers employees asked confirm writing comply requirements introduced global management population existing contracts reviewed gender implementing gsk spirit men women total contacted suppliers far consumer healthcare india gain agreement standards date country diverse india creating bands b unified spirit culture critical success companies declined cooperate bands c gsks consumer healthcare business bands c following yet responded request main product horlicks major total consumer brand india business employs people ten sites employees questions human rights issues corporate executive team vice presidents senior drawn across india huge vice presidents added standard list topics discussed differences background religion director level manager level supplier visits procurement ehs culture least four different languages global audit teams commonly spoken workplace year seen increase site developed initiatives bring number women management positions supplier found meet standards gsk spirit life enable employees company work achieve compliance understand relevance indian working conduct regular audits ensure environment supported business improved performance wide tools spirit website regularly updated games quizzes report ethnicity data us employees line requirements terminate apply spirit practice people colour accounted contract supplier work increased slightly towards compliance companys nabha manufacturing site us workforce intend rural punjab area literacy rates low uses posters cricket cartoons collect report ethnicity data uk illustrate spirits principles employees operations also made motivational film use team meetings ethnicity us employee population employees manufacturing sites encouraged get involved global total us operational excellence campaign demonstrate passion work employees developing jdi concept simple ideas improve efficiency people colour effectiveness every one employees nabha contributed least one jdi including ideas improve health safety reduce waste site jdis developed sonepat plant helped save employees rewarded ideas spirit recognition awards companys focus getting culture right helped gain recognition one indias top employers declared fifth best employer annual business todayhewitt awards partly determined employee feedback corporate responsibility report corporate responsibility report research developme medical research give rise ethical concerns engage openly constructive debate matters discuss disclosure clinical trial information use animals research evaluating potential new medicines believe healthcare decisions clinical trials essential mandatory made knowledge relevant step developing new treatments trials information gsk supports scientific medical may also conducted medicine progress making results clinical trials market investigate widely available whenever possible role treatment patients publish clinical trial results peerreviewed studies first concern safety scientific medical journals conference wellbeing trial participants abstracts proceedings research future patients healthcare communities look sources current information clinical trials conducted accordance applicable laws regulations well worked pharmaceutical recognised principles good clinical practice companies help clarify industrys legally obliged disclose data approach communication clinical trial clinical trials regulatory authorities results develop phrma principles seek approval new product conduct clinical trials communication clinical trial results fully support approval market product given principles apply clinical regulators satisfied product safe studies worldwide effective manufactured high consistent quality standards medicine particular reaffirm commitment vaccine approved marketing timely communication meaningful continue provide regulatory authorities results controlled clinical trials marketed safety information products investigational products approved marketing whether results positive negative corporate responsibility report research development nd nt review discuss manuscripts advancing management number publications gsk clinical trials clinical investigators conducted gsk heart disease sponsored studies submitted heart failure serious condition five million people affected us alone half journal conference publication ensure anyone contributes patients die within five years diagnosis new treatments urgently significantly study writing required revising manuscript receives appropriate gsk partnering another company rose recognition author contributor challenge investigating new uses manuscript published coreg gsk betablocker medicine publish results gathered centres treating high blood pressure involved multicentre trial clinical trial results positive individual centres demonstrating adding coreg current medication reduced mortality rate among publication journals many conferences patients heart failure slowed subject peer review discretion progression disease help journal editors conference organisers patients live longer feel better means gsk guarantee product licence expanded clinical trial information published coreg prescribed doctors ways therefore assessing additional treatment heart failure well options communicate clinical trial information number publications year depends hypertension number trials completed first time betablocker number accepted publication shown effective safe treating heart failure previously believed papers describing results betablockers unsafe heart failure gsks clinical trials published journals patients conferences corporate responsibility report animal research committed rs reducing number animals used may fluctuate animal research essential understand number animals used study refining year year depends several factors disease enables us evaluate studies minimise pain maximise number compounds research effectiveness safety new medicines information obtained animal development regulatory requirements given people regulations require replacing animal studies alternative methods introduction new nonanimal research use animals establish new medicines wherever possible techniques safe test types vaccines batch produced example replaced many animal laboratories comply strict national studies new research methods laws guidelines codes conduct believe important explain need computer modelling tests isolated cells regularly inspected government agencies animal research open tissues refined many procedures employees laboratories working host visits schools colleges use noninvasive techniques magnetic behalf must also follow gsk code practice animal welfare organisations rspca resonance imaging helped reduce research teams ensure studies refined stakeholders laboratories number animals used study minimise animal suffering uk also made visits uk schools discuss issues arising animal run award programmes encourage also obtain additional independent research consult organisations researchers find alternative approaches evaluation association assessment nuffield council bioethics use animals gsks rd chairman accreditation laboratory animal care universities federation animal welfare presents several animal welfare awards aaalac international gives year employees made outstanding accreditation sites meet highest gsk animal research facilities us advances implementing rs annual standards seven gsks animal europe japan research approximately european gsk laboratory animal welfare prize laboratories us uk accredited conducted external contractors external laboratories awarded made good progress working towards behalf individuals groups developed new accreditation sites continental europe techniques enhance ability implement japan plan complete process soon animals use rodents rs years winner norwegian possible remaining includes fish amphibians reference centre laboratory animal science rabbits pigs dogs cats primates alternatives approach achieving results number animals used gsk broadly nine years ago despite significant increase rd activity animals used research change rd activity compared number animals used gsk year rd activity animals used ecnis egnahc mice rats guinea pigs rodents others figures normalised levels corporate responsibility report discussion others engaging stakeholders important aspect approach corporate responsibility believe essential listen peoples views communicate opinions externally interact many different people communication employees employee satisfaction surveys give us feedback groups interested internal communication particularly important company programmes identify business affected products aim keep everyone well informed areas better global survey operations employees investors doctors involved company activities seek involved managers around patients suppliers nongovernmental feedback range initiatives world next management survey organisations ngos multilateral ensure reach employees right across take place agencies governments local company include local level many sites produce regular communities much discussion newsletters staff often spotlighting takes place part normal course mygsk global intranet site updates environment health safety issues business also meetings company industry news qa programmes specifically review corporate employees put questions confidential feedback mechanisms enable responsibility issues example directly ceo questions employees raise concerns include socially responsible investors ngos answered month integrity helplines uk us behind news section gsk europe works councils european intranet giving companys position employee consultation forum provide regular important issues linked press clippings opportunities employees company gsk management discuss issues spirit internal magazine available employees companywide four times year events programme meetings events enable employees levels meet ceo senior management discuss progress business raise questions give feedback corporate responsibility report discussion external stakeholders way interact groups depends much needs type work ways interact stakeholder type communication healthcare meet regularly doctors pharmacists tell products discuss issues professionals concerns may also conduct market research among doctors healthcare example doctors professionals get feedback pharmacists work medical organisations develop sponsor continuing medical education doctors healthcare professionals accredited training courses asthma care nurses partner healthcare professionals design conduct clinical trials research projects research results including clinical trials peerreviewed published medical journals governments regular dialogue regulators share information new science technologies regulators example supported genetic research education programme discuss issues raised genetics potential applications healthcare operations liaise regularly environment health safety authorities ensure complying fully legal obligations many specialist environment health safety employees also participate government committees consultations help develop better regulation future sponsored annual conference uk environment agency gsks work green chemistry acknowledged presentation baroness young chief executive agency investors senior managers present final yearend results institutional investors analysts london new york also teleconferences release quarterly results presentations accessed via website annual general meeting takes place london includes business presentation shareholders directors available answer questions senior managers discuss companys plans objectives governance institutional shareholders includes regular meetings participation external investor conferences held rd day december inform investors products development pipeline annual corporate responsibility forum investors held july senior gsk managers expertise relevant areas met representatives investment funds rating agencies responded questions also meet regularly investors discuss corporate responsibility policies performance meetings held included discussions key impact areas addressed report corporate responsibility report stakeholder type communication nongovernmental discuss approaches healthcare needs developing countries ngos mdecins sans organisations frontires freedom hunger oxfam communities work ngos patient groups consumer groups example smoking cessation asthma vaccination campaigns community investment programmes work partnership organisations community groups meet together regularly around world evaluate progress meeting local community needs environment health safety ehs workshop september brought together key ngos trade unions government representatives discuss environmental performance longterm strategy achieving leadership excellence ehs key issues highlighted discussion form part improvement programme partner number environmental ngos examples include sponsoring green alliance project raise awareness links environment health funding earthwatch send school teachers conservation projects host tours laboratories visit schools help improve understanding scientific research example use animals many operations produce newsletters keep local communities informed work year several sites host open days many gsk sites employees undertake projects improve environment local area number operations also outreach projects example horlicks plant rajahmundry india recognised ceos ehs excellence award community partnership local projects including provision drinking water villages experiencing drought donation desks chairs schools building bridge improve access school organising deworming programme children scientific community collaborate academics researchers pharmaceutical companies research develop new treatments encourage transfer expertise skills work education authorities develop sponsor initiatives science education schools example inspire programme hold regular science policy conference uk partnership government non government stakeholders discuss issues common interest meeting discuss clinical sciences uk sponsor university research environment health safety issues including projects green chemistry ecoefficiency alternative technologies reduce environmental impacts regularly meet un agencies including unaai unicef global fund fight multilateral agencies aids tb malaria discuss wide range issues include addressing hivaids epidemic preferential pricing arrangements creating publicprivate partnerships rd diseases developing world targeting product donations collaborate ministries health partners part global alliance eliminate lf take part annual whoifpma round tables industry discuss partnership opportunities improve global health corporate responsibility report web references corporate website found wwwgskcom websites cited report wwwunorgoverviewrightshtml wwwoecdorgdataoecdpdf wwwiloorgpublicenglishstandardsnormindexhtm httpusgskcomcard wwwtogetherrxcom wwwcommitmenttoaccessgskcom wwwbridgestoaccessgskcom wwwgskcomaboutpricinghtm wwwtheglobalfundorg wwwwhointbypublicationsdocumentsentreatingmillionbypdf wwwstategovpafrlsfshtm wwwmmvorg wwwastmhorgindexhtml wwwgskcomcommunityindexhtm wwwfilariasisorg wwwgskcompositiveactionindexhtm wwwgskfrgskfondmphtml wwwgskcommalariaindexhtm wwwchildrenshealthfundorgrmihtml wwwgskcomcommunityimpactawardsukhtm wwwgskcomcommunityimpactawardsushtm wwwgskcomserserserhtml httpoighhsgovfrauddocscomplianceguidancepharmacymfgnonfrpdf wwwifpmaorgnewsnewsmarketaspx wwwgskcomfinancialrepsehsgskehshtm wwwphrmaorgpublicationspolicypdf wwwgskcomaboutanimalresearchhtm wwwrdsonlineorgukpagesaspitoolbaridipageid wwwaaalacorg corporate responsibility report internet information company available glaxosmithklines corporate website wwwgskcom head office registered office glaxosmithkline plc great west road brentford middlesex tw gs uk tel contact company directly corporate responsibility issues csrcontactgskcom reports annual review feel better live longer review major themes abridged version financial results improving health every day annual review annual report feel better live longer full financial statements improving performance every day annual report produced corporate communications glaxosmithkline corporate feel better live longer responsibility report design consultancy salterbaxter review corporate responsibility consultancy context commitment society environment photograph courtesy monika graff printed uk colourhouse paper making difference used production document made every day pulps harvested sustainable forests also using sawmill residues forest thinnings corporate responsibility report elemental chlorinefree maikminpgr oav idnigff ehreeanlcthe eevveerryy ddaayy product names throughout publication indicated italics trademarks glaxosmithkline plc subsidiaries associated every day around world glaxosmithkline companies exception levitra trying improve peoples lives positive trademark bayer ag nicoderm trademark impact stakeholders years reports aventis sa used licence emphasise farreaching commitment groupwwwgskcom annual review